ClinicalTrials.gg
Not yet recruitingNCT06640140Train-CRUpdated Oct 15, 2024

Effects of a Supervised Training Program on Functional Capacity in Patients With HF and Cardiorenal Syndrome

An interventional study of Supervised aerobic plus strength training in Heart Failure and Cardiorenal Syndrome, sponsored by Fundación para la Investigación del Hospital Clínico de Valencia. Not yet recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-15.

Primary conditionCardio-Renal SyndromeRegistry: Heart FailureReclassifiedWhy we changed it
Registry
Heart Failure — the first condition term the registry derived for this study.
ClinicalTrials.gg
Cardio-Renal Syndrome
Why
  1. The study's listed conditions name Cardio-Renal Syndrome, a narrower term within Heart Failure.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Fundación para la Investigación del Hospital Clínico de Valencia · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Sep 2025, 1 year 2 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
26
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a prospective study, blinded for the evaluator, randomized (1:1) to receive standard management alone or combined with a training program (aerobic combined with strength exercises) that will be carried out in a single center. After randomization, patients will be clinically evaluated. The primary endpoint (peakVO2) will be assessed by cardiopulmonary exercise testing combined with echocardiography (echo-CPET) at 12 weeks. Ambulatory patients with heart failure and cardiorenal syndrome and functional class NYHA II-III will be enrolled. A sample size estimation [alfa: 0.05, power: 80%, a 20% loss rate, and at least a delta change of mean peakVO2: +2,4 mL/kg/min (SD±2)] of 26 patients (13 per arm) would be necessary to test our hypothesis.

Read the detailed description

Heart failure (HF) is a highly prevalent clinical entity that predominantly affects elderly people with comorbidities. Among these, chronic kidney disease is particularly frequent, complicating disease management and worsening prognosis. Supervised training programs in patients with HF have improved functional capacity and reduced hospitalizations. However, the evidence is scarce regarding the effects of a supervised training program on patients with HF and cardiorenal syndrome. This work aims to evaluate the effect of a supervised exercise program for 12 weeks in patients with HF and cardiorenal syndrome on peak oxygen consumption (peakVO2).

This is a prospective study, blinded for the evaluator, randomized (1:1) to receive standard management alone or combined with a training program (aerobic combined with strength exercises) that will be carried out in a single center. After randomization, patients will be clinically evaluated. The primary endpoint (peakVO2) will be assessed by cardiopulmonary exercise testing combined with echocardiography (echo-CPET) at 12 weeks. Ambulatory patients with heart failure and cardiorenal syndrome and functional class NYHA II-III will be enrolled. A sample size estimation [alfa: 0.05, power: 80%, a 20% loss rate, and at least a delta change of mean peakVO2: +2,4 mL/kg/min (SD±2)] of 26 patients (13 per arm) would be necessary to test our hypothesis.

02

Conditions studied

  • Heart Failure
  • Cardiorenal Syndrome

Browse trials for

Keywords

  • Heart failure
  • Cardiorenal Syndrome
  • Functional Capacity
03

In context

Cardio-Renal Syndrome Reclassified

85 studies on the registry are indexed under Cardio-Renal Syndrome; 20 are open to participants now.

This study's planned enrollment of 26 is below the median of 50 across 55 interventional studies indexed under Cardio-Renal Syndrome.

Browse Cardio-Renal Syndrome studies →

Lead sponsor

Fundación para la Investigación del Hospital Clínico de Valencia is the lead sponsor of 73 studies on the registry; 18 are open to participants now.

Compared within Cardio-Renal Syndrome, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Heart Failure. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients diagnosed with heart failure according to 2021 ESC guidelines for Heart Failure.
  • Evidence of cardiorenal syndrome, defined as coexistent very high risk chronic kidney disease (CKD) (estimated [eGFR] \<30 ml/min/1.73m2 or eGFR 30 to 44 ml/min/1.73m2 and Urine Albumin-Creatinine Ratio [uACR] >30 mg/g) or rapidly progressive CKD (loss of >5 ml/min/1.73m2 in one year).
  • Stable symptomatic heart failure patients ( functional class II-III/IV) during the last month.
  • Age ≥ 18 years old.
  • Willing to provide written .

Exclusion criteria

Exclusion Criteria:

  • Inability to perform a valid baseline cardiopulmonary exercise test.
  • Significant primary severe valve disease that is considered the main symptom driver.
  • Effort angina or signs of ischemia during CPET.
  • Primary cardiomyopathies.
  • Cardiac transplantation.
  • Any other comorbidity with a of less than one year.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
26 participants (estimated)

Study arms

  • No intervention
    Usual care

    Patients allocated to this arm will receive the usual care plus explicit recommendations for home-based aerobic and strength training.

  • Active comparator
    Supervised aerobic plus strenght training

    Patients allocated to this arm will receive the usual care plus supervised aerobic and strength training.

    Behavioral: Supervised aerobic plus strength training

Interventions

  • BehavioralSupervised aerobic plus strength training

    Supervised moderate to high-intensity interval aerobic training plus moderate to high-intensity strength training.

06

What researchers measure

Primary outcomes

  1. Peak oxygen consumption

    Primary outcome: changes in peak oxygen consumption between groups at 12 weeks. Description: Peak oxigen consumption (also known as maximal functional capacity) will be evaluated using incremental and symptom-limited cardiopulmonary exercise testing on a semi-supine bicycle ergometer (coupled with stress echocardiography), beginning with a workload of 10 Watts and increasing gradually in a ramp protocol at 10-Watts increments every 1 minute. Peak oxygen consumption (PeakVO2) is defined as the highest value of VO2 during the last 20 seconds of exercise. Unit of measure of peak oxygen consumption: mL/kg/min (this is a directly reported measure from the cardiopulmonary exercise testing, not an aggregated or derived calculation).

    Time frame: The investigators will evaluate peak oxygen consumption at baseline (week 0) and at week 12.

Secondary outcomes

  1. Kansas City Cardiomyopathy Questionnaire

    The Kansas City Cardiomyopathy Questionnaire includes 23 items that map to 7 domains: symptom frequency, symptom burden, symptom stability, physical limitations, social limitations, quality of life, and self-efficacy (the patient's understanding of how to manage their heart failure). All Kansas City Cardiomyopathy Questionnaire domains are scaled from 0 to 100, where scores represent health status as follows: 0 to 24, very poor to poor; 25 to 49, poor to fair; 50 to 74, fair to good; and 75 to 100, good to excellent. A change of 5 points is considered to be a small but clinically important change, whereas changes of 10 and 20 points are considered moderate-to-large and large-to-very-large clinical changes.

    Time frame: The investigators will evaluate Kansas City Cardiomyopathy Questionnaire at baseline (week 0) and at week 12.

  2. Chronotropic index

    Secondary outcome: changes in chronotropic response between groups at 12 weeks. Description: Chronotropic index is an index calculated in a maximal cardiopulmonary exercise testing to assess heart rate response to exercise. The chronotropic index is evaluated by the following formula, including heart rate at peak effort, heart rate at rest and age. Chronotropic index: (peak heart rate-rest heart rate)/ \[220-age-rest heart rate)\]. The chronotropic index has no units of measure.

    Time frame: The investigators will evaluate chronotropic index at baseline (week 0) and at week 12.

Other outcomes

  1. Age

    Age at the moment of assessment that will be used to further calculate chronotropic index. Units: years.

    Time frame: The investigators will evaluate age at baseline (week 0) and at week 12.

  2. Peak heart rate

    Peak heart rate is defined as heart rate at the end of exercise of the maximal cardiopulmonary exercise testing and will be used to further calculate chronotropic index. Units: beats per minute.

    Time frame: The investigators will evaluate peak heart rate at baseline (week 0) and at week 12.

  3. Heart rate at rest

    Heart rate at rest is defined as heart rate at the beginning of the maximal cardiopulmonary exercise testing and will be used to further calculate chronotropic index. Units: beats per minute.

    Time frame: The investigators will evaluate heart rate at rest at baseline (week 0) and at week 12.

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2024; primary completion for Sep 2025, 11 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 8, 2024
First posted
Oct 15, 2024
StartEst.
Oct 8, 2024
Primary completionEst.
Sep 2025
CompletionEst.
Dec 2025
Last update
Oct 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06640140
Lead sponsor
Fundación para la Investigación del Hospital Clínico de Valencia
Responsible party
Sponsor
First posted
Oct 15, 2024
Start date
Oct 8, 2024 (estimated)
Primary completion
Sep 2025 (estimated)
Completion
Dec 2025 (estimated)
Last update
Oct 15, 2024

Study contacts

Patricia Fernández, PhD
Contact
patricia.fernandez@incliva.es
961973536 ext. +34
Gonzalo Núñez Marín, MD
principal investigator · Instituto de investigación sanitaria INCLIVA

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion